Signify Bio

- 06/06/2025
- Unknown
- $15,000,000
Signify Bio is a biotechnology company transforming the development of in situ protein therapeutics by leveraging the human body’s natural ability to produce proteins. Guided by its mission to create personalized medicines for all, Signify combines the precision of signal peptide engineered control with the speed and versatility of mRNA encoded design. The company’s SEND platform and iPhos lipid nanoparticles enable targeted and localized delivery of therapeutic proteins, addressing significant unmet needs across various diseases. Through innovative science, Signify Bio is committed to advancing solutions that make a meaningful difference for patients worldwide.
- Industry Biotechnology Research
- Website https://signifybio.com/
- LinkedIn https://www.linkedin.com/company/signify-bio/
Related People
RA Session IICo Founder

RA Session II is a serial biotech entrepreneur with more than 20 years of experience in the life sciences industry, primarily in business development, corporate strategy, finance and advisory roles. He is the Co-founder, President, and CEO of Signify Bio, a company on a mission to create personalized medicines for all by combining the promise of signal peptide engineered control with the speed and power of mRNA encoded design. He founded Taysha Gene Therapies and served as its CEO, President and Board Member. Previously, he served as Chief Business Officer of the gene therapy subsidiaries of BridgeBio, as well as Senior Vice President of Corporate Strategy and Business Development at AveXis.
Specialties: Biopharmaceuticals, Entrepreneurship, M&A, Licensing, Valuation, and Strategic PlanningRA